Pfizer Inc (PFE) reported robust financial results for the third quarter of fiscal 2025, surpassing analyst expectations. The company's earnings per share (EPS) reached $0.87, significantly higher than the consensus estimate of $0.64, marking a $0.23 increase. Revenue for the quarter matched expectations at $16.7 billion.
This performance underscores Pfizer's strong operational fundamentals, reflecting its position as a leading research-based global biopharmaceutical company. Pfizer engages in the discovery, development, manufacture, marketing, and distribution of biopharmaceutical products worldwide, with a diverse portfolio that includes oncology, primary care, and specialty care products.
The company will host an earnings conference call at 8:00 AM EST to discuss these results and provide further insights into its business performance. Investors may find value in reviewing the full earnings release and management commentary for a comprehensive understanding of the quarter's results and future outlook.
As of November 7, 2025, Pfizer's market capitalization stands at $137.45 billion, with a price-to-earnings (P/E) ratio of 13.98. The company has an EPS (TTM) of 1.72 and a notable dividend yield of 692.2%. Upcoming earnings are scheduled for August 2, 2026, with an EPS estimate of $0.6775 and revenue expected at $14.4 billion.